Idorsia News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

12.01.22	Jennifer Aniston partners with Idorsia U.S. to launch ‘Seize the Night & Day’ campaign inspiring Americans to understand their relationship with sleep (GlobeNewswire)
10.01.22	Idorsia presents at the 40th J.P. Morgan Healthcare Conference – Ready for first product launches – QUVIVIQ (daridorexant) approved by the US FDA (GlobeNewswire)
10.01.22	Idorsia presents at the 40th J.P. Morgan Healthcare Conference – Ready for first product launches – QUVIVIQ (daridorexant) approved by the US FDA (GlobeNewswire)
10.01.22	Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment of adults with insomnia (GlobeNewswire)
10.01.22	Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment of adults with insomnia (GlobeNewswire)
13.12.21	Idorsia to further characterize lucerastat for the treatment of Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study (GlobeNewswire)
13.12.21	Idorsia to further characterize lucerastat for the treatment of Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study (GlobeNewswire)
01.11.21	Idorsia to advance cenerimod into Phase 3 development for treatment of patients with systemic lupus erythematosus (GlobeNewswire)
01.11.21	Idorsia to advance cenerimod into Phase 3 development for treatment of patients with systemic lupus erythematosus (GlobeNewswire)
27.10.21	Johnson & Johnson partially converts its convertible loan (GlobeNewswire)
27.10.21	Johnson & Johnson partially converts its convertible loan (GlobeNewswire)
26.10.21	Idorsia publiziert die Finanzergebnisse für das dritte Quartal 2021 – Das Unternehmen kommt weiter voran; Einführungsvorbereitungen für Schlüsselmärkte auf gutem Weg (GlobeNewswire)
26.10.21	Idorsia announces financial results for the third quarter 2021 – company progressing and launch preparations in key markets well underway (GlobeNewswire)
11.10.21	Idorsia announces the results of MODIFY, a Phase 3 study of lucerastat in Fabry disease (GlobeNewswire)
11.10.21	Idorsia announces the results of MODIFY, a Phase 3 study of lucerastat in Fabry disease (GlobeNewswire)
29.07.21	Application of Jean-Paul and Martine Clozel regarding the exemption from the offer obligation in relation to Idorsia Ltd (GlobeNewswire)
29.07.21	Application of Jean-Paul and Martine Clozel regarding the exemption from the offer obligation in relation to Idorsia Ltd (GlobeNewswire)
28.07.21	Idorsia announces the reference share price and the initial conversion price of convertible bonds successfully placed today (GlobeNewswire)
28.07.21	Idorsia announces the reference share price and the initial conversion price of convertible bonds successfully placed today (GlobeNewswire)
28.07.21	Idorsia successfully completes the offering of convertible bonds, securing funding to develop the company into a leading biopharmaceutical company (GlobeNewswire)
28.07.21	Idorsia successfully completes the offering of convertible bonds, securing funding to develop the company into a leading biopharmaceutical company (GlobeNewswire)
28.07.21	Idorsia launches the offering of convertible bonds to fund the development of the company into a leading biopharmaceutical company (GlobeNewswire)
28.07.21	Idorsia launches the offering of convertible bonds to fund the development of the company into a leading biopharmaceutical company (GlobeNewswire)
27.07.21	Idorsia gibt Finanzergebnisse für das erste Halbjahr 2021 bekannt – Entwicklung zum vollständig integrierten biopharmazeutischen Unternehmen schreitet dynamisch voran (GlobeNewswire)
27.07.21	Idorsia announces financial results for the first half 2021 – Building momentum towards becoming a fully-fledged biopharmaceutical company (GlobeNewswire)
20.07.21	Invitation to Idorsia's half year financial results 2021 webcast and conference call (GlobeNewswire)
20.07.21	Invitation to Idorsia's half year financial results 2021 webcast and conference call (GlobeNewswire)
28.06.21	Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction (GlobeNewswire)
28.06.21	Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction (GlobeNewswire)
09.06.21	Idorsia to present new Phase 3 data on daridorexant in insomnia at SLEEP 2021 (GlobeNewswire)
09.06.21	Idorsia to present new Phase 3 data on daridorexant in insomnia at SLEEP 2021 (GlobeNewswire)
25.05.21	European Commission approves Ponvory (ponesimod) for the treatment of adults with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features (GlobeNewswire)
25.05.21	European Commission approves Ponvory (ponesimod) for the treatment of adults with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features (GlobeNewswire)
12.05.21	Idorsia holds its Annual General Meeting of Shareholders (GlobeNewswire)
12.05.21	Idorsia hält ordentliche Generalversammlung ab (GlobeNewswire)
22.04.21	Idorsia announces financial results for the first quarter 2021 – substantial progress made across the pipeline – launch preparations well underway (GlobeNewswire)
22.04.21	Idorsia gibt Finanzergebnisse für das erste Quartal 2021 bekannt – markante Fortschritte bei der gesamten Pipeline – Einführungsvorbereitungen auf gutem Weg (GlobeNewswire)
01.04.21	Idorsia veröffentlicht Ankündigung der ordentlichen Generalversammlung 2021 (GlobeNewswire)
01.04.21	Idorsia issues Notice of the 2021 Annual General Meeting of Shareholders (GlobeNewswire)
26.03.21	The European Medicines Agency’s CHMP issues a positive opinion recommending marketing authorisation for Ponvory (ponesimod) to treat adults with relapsing forms of multiple sclerosis (GlobeNewswire)
26.03.21	The European Medicines Agency’s CHMP issues a positive opinion recommending marketing authorisation for Ponvory (ponesimod) to treat adults with relapsing forms of multiple sclerosis (GlobeNewswire)
19.03.21	US FDA approves Ponvory (ponesimod) to treat adults with relapsing forms of multiple sclerosis (GlobeNewswire)
19.03.21	US FDA approves Ponvory (ponesimod) to treat adults with relapsing forms of multiple sclerosis (GlobeNewswire)
10.03.21	FDA accepts the new drug application for review of Idorsia’s daridorexant for the treatment of adult patients with insomnia (GlobeNewswire)
10.03.21	FDA accepts the new drug application for review of Idorsia’s daridorexant for the treatment of adult patients with insomnia (GlobeNewswire)
03.03.21	Idorsia submits European marketing authorisation application for daridorexant for the treatment of adult patients with insomnia (GlobeNewswire)
03.03.21	Idorsia submits European marketing authorisation application for daridorexant for the treatment of adult patients with insomnia (GlobeNewswire)
01.03.21	Idorsia submits NDA for clazosentan to Japanese PMDA (GlobeNewswire)
01.03.21	Idorsia submits NDA for clazosentan to Japanese PMDA (GlobeNewswire)
04.02.21	Idorsia announces financial results for 2020 – a successful year marked by outstanding clinical data (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Roche Hldg G	255.50	0.75 %	K V
Nestle	74.88	0.62 %	K V
CieFinRichemont	137.90	0.40 %	K V
Swiss Life Hldg	699.60	0.32 %	K V
Swisscom	504.50	0.30 %	K V
Sika	215.80	-0.37 %	K V
Givaudan	3’966.00	-0.40 %	K V
Lonza Grp	535.80	-0.41 %	K V
Geberit	514.60	-0.46 %	K V
ABB	49.07	-0.95 %	K V

mehr

31.12.24		SPI-Papier Idorsia-Aktie: So viel Verlust wäre bei einem Investment in Idorsia von vor 5 Jahren angefallen
27.12.24		SPI aktuell: SPI zum Ende des Freitagshandels in der Gewinnzone
27.12.24		Gewinne in Zürich: SPI am Nachmittag freundlich
27.12.24		SIX-Handel: SPI präsentiert sich am Mittag fester
27.12.24		Börse Zürich in Grün: SPI präsentiert sich zum Start des Freitagshandels fester
24.12.24		SPI-Papier Idorsia-Aktie: So viel Verlust hätte eine Investition in Idorsia von vor 3 Jahren bedeutet
23.12.24		Freundlicher Handel: SPI legt letztendlich zu
23.12.24		SPI-Handel aktuell: So steht der SPI aktuell